Atypical Hemolytic Uremic Dyndrome
New atypical hemolytic uremic syndrome research, summarized each month in plain language.
2026 so far: In January 2026 to September 2026, real-world studies and withdrawal cohorts added detail on how complement blockers are used, monitored, and sometimes stopped in selected aHUS patients, with relapse risk appearing more common in complement-abnormal subgroups. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- C5 blockers in practice. Routine-care cohorts added timing and outcome benchmarks for C5 blockade.
- Stopping with monitoring. Withdrawal studies clarified who relapsed and how monitoring enabled restart.
- Infection and safety. Registry prevention data and case reports underscored persistent infection risk.
- Anti-CFH and transplant. Subtype-focused cohorts clarified recovery, relapse timing, and transplant recurrence patterns.
- Monitoring and risk. Reports added practical monitoring candidates, from drug levels to severity markers.
New
September 2026
- Ravulizumab and labs. During remission, blood tests suggested the complement target was blocked.
- Heart attack outcomes. After STEMI, prior C5 blockers were linked to more kidney and clot events.
- Child kidney recovery. About half had full kidney recovery by two years.
- Post-transplant relapse. Recurrence was reported only with complement gene changes.
August 2026
- Complement medicines. Case reports linked these drugs to quick blood and kidney recovery.
- Early severity signs. Shock, heart failure, or ventilation early linked to worse outcomes.
- Transplant monitoring tests. Small studies explored markers to track transplant-related TMA risk.
July 2026
- Common triggers. aHUS sometimes followed major stress and did not resolve quickly.
- Complement blockers. Blood counts often improved sooner than kidney function.
- Hospital safety signals. In septic shock, C5 inhibitors were linked to more complications.
June 2026
- Biosimilar outcomes. Platelets often normalized, with few new TMA episodes.
- Kidney function change. Kidney function improved in fewer people, often partly.
- Relapse risk markers. Some gene variants and antibodies matched certain relapse patterns.
May 2026
- Anti–factor H antibody treatment. In anti–factor H antibody aHUS, a review linked plasma exchange to faster improvement in blood counts than eculizumab.
- Common episode triggers. Case reports linked aHUS episodes to pregnancy or postpartum illness, infections, and kidney transplant.
- Meningococcal infection on ravulizumab. One report described meningococcal meningitis during ravulizumab even with vaccination and preventive antibiotics.
- CFHR deletion testing. A ddPCR lab method matched an established test for detecting CFHR gene deletions in 41 samples.
April 2026
- Complement blockers in complex cases. More real-world reports described complement-blocking treatment being used in difficult, high-risk situations, with improvement described in thrombotic microangiopathy.
- Kidney recovery in children. In a small report, children treated with eculizumab had kidney lab measures improve quickly, and all were off dialysis by 4 weeks.
- NETs and disease activity. Higher levels of neutrophil extracellular traps (NETs) were linked to more active disease in patients.
March 2026
- Eculizumab in children. In real-world pediatric reports, many children reached remission and kidney-related measures often improved during eculizumab treatment.
- Stopping eculizumab. In some stable patients, eculizumab was stopped with close monitoring and some remained stable, but relapses still occurred.
- Ravulizumab side-effect timing. In a large side-effect report analysis, many ravulizumab symptoms were reported within about 30 days, and the analysis also flagged possible signals not listed on the label.
- Genetics and relapse risk. Some complement-related gene findings were linked to higher relapse risk, but many patients had no clear genetic result.
February 2026
- Ravulizumab outcomes in routine care. In routine-care records, many adults on ravulizumab had improving blood counts and kidney measures, and a complete TMA response was reported in 68% by 12 months.
- Complement markers during episodes. In some reports, complement activation markers were high during acute episodes and decreased as patients recovered, which is one way teams track disease activity over time.
- Triggers and overlapping conditions. Case reports described aHUS-like illness alongside infections, autoimmune conditions, or other rare genetic diseases, and genetic changes sometimes increased risk but did not reliably predict who becomes ill.
January 2026
- Stopping eculizumab with monitoring. In a monitored stopping plan, most people did not relapse after stopping eculizumab, and relapses were reported only in people with complement dysregulation.
- Measuring drug effect over time. In a small pediatric remission group, ravulizumab levels stayed above target with strongly suppressed complement activity, and separate modeling suggested eculizumab blood levels could help estimate future levels.
- Preventing meningococcal infection. Registry data linked vaccination plus continuous antibiotics with fewer invasive meningococcal infections during C5 blockade, while missed doses and rare antibiotic resistance were still reported.
- How the alternative pathway causes injury. Lab and mouse studies found that blocking the alternative pathway (including at C3 or C5) reduced complement-driven injury patterns on blood vessel cells, and tested another way to switch off the alternative pathway.
Get the monthly update by email
Subscribe here to receive an email when a new monthly atypical hemolytic uremic syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).